{Reference Type}: Journal Article
{Title}: Stem cell treatment reduces T cell apoptosis in COPD patients with chronic bronchitis but not with emphysema.
{Author}: Eryüksel E;Tunca Z;Mercancı Z;Kılıç SS;Kocakaya D;Akdeniz E;Öztop NE;Çetin E;Akkoç T;
{Journal}: Tissue Cell
{Volume}: 89
{Issue}: 0
{Year}: 2024 Aug 26
{Factor}: 2.586
{DOI}: 10.1016/j.tice.2024.102452
{Abstract}: <B>BACKGROUND: </B>Chronic obstructive pulmonary disease (COPD) is a prevalent and preventable condition. Mesenchymal stem cell (MSC) therapy is being explored to aid in the regeneration of lung cells and airway structure, aiming to restore lung function.<BR><B>OBJECTIVE: </B>To examine varied responses of MSCs when cultured with peripheral blood mononuclear cells (PBMCs) from different COPD phenotypes, patients were grouped into ACOS, emphysema, and chronic bronchitis categories.<BR><B>METHODS: </B>PBMCs from these groups and controls were co-cultured with MSCs derived from dental follicles, revealing differing rates of apoptosis among COPD phenotypes compared to controls.<BR><B>RESULTS: </B>While the chronic bronchitis group exhibited the least lymphocyte viability (p<0.01), introducing MSCs notably enhanced viability across all phenotypes except emphysema, with the chronic bronchitis group showing the most improvement (p<0.05).<BR><B>CONCLUSIONS: </B>Stem cell therapy might reduce peripheral lymphocyte apoptosis in COPD, with varying responses based on phenotype, necessitating further research to understand mechanisms and optimize tailored therapies for each COPD subtype.